News

Entyvio (vedolizumab) and Xeljanz (tofacitinib) are the most commonly studied therapies, according to the Pfizer-sponsored review, and when the two were compared, Xeljanz showed higher remission rates.

The two clinical trials will enroll patients recovering from surgical procedures.

Here's what you missed this week on Managed Healthcare Executive.

Kerri Tanner, Pharm.D., the chief pharmacy officer of PayerAlly, says payers are looking for ways to rein in the escalating costs of specialty pharmacy drugs beyond the traditional techniques used by pharmacy benefit managers.

Patrick Cooney, president of The Federal Group, says elimination of spread pricing is one of the three key elements of the PBM legislation that he believes is likely to pass during the lame-duck session of Congress after the Nov. 5 election.

Greg Baker, CEO of AffirmedRx, did not hold back in criticizing CVS Caremark, Optum Rx and Express Scripts and their group purchasing organizations today at the PBMI Annual National Conference.

Patrick Cooney, president of The Federal Group, a Washington, D.C., lobbying firm says prospects for legislation passing this year, albeit during the post-election lameduck session, are good partly because the PBM legislation would produce Medicare savings that could be put toward other uses.

Telehealth has become a permanent part of U.S. healthcare delivery, and states are taking steps to regulate it

The IQVIA vice president and frequent speaker at pharmacy and managed care meetings said he will retire in May 2025.

HIV treatments using a single pill improve adherence and are cheaper to maintain.

Pharmacy benefit managers aren't getting mentioned on the campaign trail, but there are some signs Congress could enact reform legislation after the Nov. 5 election.

Joseph Shields of TransparencyRx predicts there will be more lawsuits against self-funded employers alleging they’ve mismanaged prescription drug benefits through PBMs.

During an interview, Joseph Shields of TransparencyRx discusses the PBM legislation that is expected to move forward in Congress in the next few months.

Breast cancer patients were also less likely to have a breast reconstruction than patients living elsewhere.

A nomogram based on four pulmonary factors is helpful but not a substitute for clinical judgment, say the authors.

Reproductive rights and abortion: The hottest healthcare issue

Individualized digital twins offer the prospect of better predicting individual patients’ disease progression and response to therapy.

Cell and gene therapies are becoming almost an everyday clinical reality. But the price tags? They still have shock value. Payers and providers are working out single-case agreements ahead of when the therapies are given.

A positive result for Bruton’s tyrosine kinase inhibitor after the drug had been put on partial clinical hold due to concerns about liver toxicity.

Sebetralstat would be the first oral, on-demand treatment for hereditary angioedema if approved.

As supplemental screening for breast cancer becomes more common, the modeling study supplies long-term projections of how many deaths could be averted but also how many false-positive biopsy recommendations would be added.

The approval comes five months after the FDA approved Winrevair.

Here’s what you missed this week on Managed Healthcare Executive.

Emergent BioSolutions is planning to donate 50,000 doses of the mpox vaccine to countries in Central Africa.

As Trilliant Health's Chief Research Officer, Sanjula Jain, Ph.D., and her team discovered that telehealth use is mostly driven by personal preferences — consumers who love the convenience, while others still prefer seeing a doctor in person because they think it's better quality. Listen in on the final interview of a three-part video series

Projections calculated for AARP show that 8.4% of Part D enrollees will benefit from the Inflation Reduction Act's $2,000 cap on out-of-pocket costs that goes into effect in 2025.

Sanjula Jain, Ph.D., chief research officer at Trilliant Health spoke with Managed Healthcare Executive in this part two interview on recent research that revealed where telehealth use stands after the pandemic. While its use is declining, Jain advised what areas are of best focus for investment.